{
  "trial_data": [
    {
      "date": "02/25/2022",
      "title": "Urinary Incontinence CCT02252022",
      "specializations": ["Research Center", "Urology"],
      "applications": [
        {
          "date": "02/25/2022",
          "submitted_by": "Yoany Rodriguez",
          "investigator": "Juvenal Martinez",
          "status": "new",
          "note": "n/a"
        }
      ],
      "description": "We are working with a sponsor on the above mentioned study. If you are interested and treat this indication please let us know. Inclusion Criteria: Women or men 22-80 years of age Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period Greater than or equal to 6-month history of UUI diagnosis Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) Willing to abstain from OAB medications for the duration of the study Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires Ambulatory and able to use the toilet independently and without difficulty Willing and capable of providing informed consent Willing and able to complete all procedures and follow-up visits indicated in the protocol Exclusion Criteria: Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year Have post-void residual urine volume >30% of total voided volume Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS]) History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain) An active implantable electronic device regardless of whether stimulation is ON or OFF Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia) Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula) End stage renal failure, GFR < 35, or dialysis History of pelvic cancer within the past two years Pelvic organ prolapse at or beyond the hymenal ring Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date Diabetes with peripheral nerve compromise or uncontrolled diabetes Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding Current active or a chronic systemic infection Condition requiring magnetic resonance imaging (MRI) of lower leg Condition requiring diathermy Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane Allergy to local anesthetic or adhesives Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications) Enrolled in another investigational or interventional device or drug trial over the study period",
      "source": "CCT-Adryna",
      "questionnaire": [
        "Are you interested?",
        "Do you actively treat this patient population?",
        "If yes, how many patients do you have in your database with Urinary Incontinence?",
        "How many of those are active and currently under treatment?",
        "On average how many new patients do you get a month?",
        "After I/E review, how many patients do you feel you can enroll in this trial?",
        "Have you done any past trials in this indication?",
        "If yes, how many?",
        "If no, how long have you been treating this patient population?",
        "This study requires a Board-Certified Urologist or Urogynecologist to function as the Principal Investigator and to implant the investigational device, Are you a Board-Certified Urologist?",
        "If no, Are you a board certified Urogynecologist?"
      ]
    },
    {
      "date": "02/25/2022",
      "title": "C",
      "specializations": ["Research Center", "Urology"],
      "applications": [
        {
          "date": "02/28/2022",
          "submitted_by": "Yoany Rodriguez",
          "investigator": "Juvenal Martinez",
          "status": "new",
          "note": "n/a"
        }
      ],
      "description": "We are working with a sponsor on the above mentioned study. If you are interested and treat this indication please let us know. Inclusion Criteria: Women or men 22-80 years of age Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period Greater than or equal to 6-month history of UUI diagnosis Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) Willing to abstain from OAB medications for the duration of the study Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires Ambulatory and able to use the toilet independently and without difficulty Willing and capable of providing informed consent Willing and able to complete all procedures and follow-up visits indicated in the protocol Exclusion Criteria: Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year Have post-void residual urine volume >30% of total voided volume Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS]) History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain) An active implantable electronic device regardless of whether stimulation is ON or OFF Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia) Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula) End stage renal failure, GFR < 35, or dialysis History of pelvic cancer within the past two years Pelvic organ prolapse at or beyond the hymenal ring Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date Diabetes with peripheral nerve compromise or uncontrolled diabetes Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding Current active or a chronic systemic infection Condition requiring magnetic resonance imaging (MRI) of lower leg Condition requiring diathermy Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane Allergy to local anesthetic or adhesives Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications) Enrolled in another investigational or interventional device or drug trial over the study period",
      "source": "CCT-Adryna",
      "questionnaire": [
        "Are you interested?",
        "Do you actively treat this patient population?",
        "If yes, how many patients do you have in your database with Urinary Incontinence?",
        "How many of those are active and currently under treatment?",
        "On average how many new patients do you get a month?",
        "After I/E review, how many patients do you feel you can enroll in this trial?",
        "Have you done any past trials in this indication?",
        "If yes, how many?",
        "If no, how long have you been treating this patient population?",
        "This study requires a Board-Certified Urologist or Urogynecologist to function as the Principal Investigator and to implant the investigational device, Are you a Board-Certified Urologist?",
        "If no, Are you a board certified Urogynecologist?"
      ]
    },
    {
      "date": "02/01/2022",
      "title": "B",
      "specializations": ["Research Center", "Urology"],
      "applications": [
        {
          "date": "02/25/2022",
          "submitted_by": "Yoany Rodriguez",
          "investigator": "Juvenal Martinez",
          "status": "new",
          "note": "n/a"
        }
      ],
      "description": "We are working with a sponsor on the above mentioned study. If you are interested and treat this indication please let us know. Inclusion Criteria: Women or men 22-80 years of age Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period Greater than or equal to 6-month history of UUI diagnosis Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) Willing to abstain from OAB medications for the duration of the study Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires Ambulatory and able to use the toilet independently and without difficulty Willing and capable of providing informed consent Willing and able to complete all procedures and follow-up visits indicated in the protocol Exclusion Criteria: Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year Have post-void residual urine volume >30% of total voided volume Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS]) History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain) An active implantable electronic device regardless of whether stimulation is ON or OFF Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia) Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula) End stage renal failure, GFR < 35, or dialysis History of pelvic cancer within the past two years Pelvic organ prolapse at or beyond the hymenal ring Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date Diabetes with peripheral nerve compromise or uncontrolled diabetes Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding Current active or a chronic systemic infection Condition requiring magnetic resonance imaging (MRI) of lower leg Condition requiring diathermy Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane Allergy to local anesthetic or adhesives Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications) Enrolled in another investigational or interventional device or drug trial over the study period",
      "source": "CCT-Adryna",
      "questionnaire": [
        "Are you interested?",
        "Do you actively treat this patient population?",
        "If yes, how many patients do you have in your database with Urinary Incontinence?",
        "How many of those are active and currently under treatment?",
        "On average how many new patients do you get a month?",
        "After I/E review, how many patients do you feel you can enroll in this trial?",
        "Have you done any past trials in this indication?",
        "If yes, how many?",
        "If no, how long have you been treating this patient population?",
        "This study requires a Board-Certified Urologist or Urogynecologist to function as the Principal Investigator and to implant the investigational device, Are you a Board-Certified Urologist?",
        "If no, Are you a board certified Urogynecologist?"
      ]
    },
    {
      "date": "01/25/2022",
      "title": "F",
      "specializations": ["Research Center", "Urology"],
      "applications": [
        {
          "date": "02/25/2022",
          "submitted_by": "Yoany Rodriguez",
          "investigator": "Juvenal Martinez",
          "status": "new",
          "note": "n/a"
        }
      ],
      "description": "We are working with a sponsor on the above mentioned study. If you are interested and treat this indication please let us know. Inclusion Criteria: Women or men 22-80 years of age Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period Greater than or equal to 6-month history of UUI diagnosis Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) Willing to abstain from OAB medications for the duration of the study Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires Ambulatory and able to use the toilet independently and without difficulty Willing and capable of providing informed consent Willing and able to complete all procedures and follow-up visits indicated in the protocol Exclusion Criteria: Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year Have post-void residual urine volume >30% of total voided volume Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS]) History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain) An active implantable electronic device regardless of whether stimulation is ON or OFF Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia) Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula) End stage renal failure, GFR < 35, or dialysis History of pelvic cancer within the past two years Pelvic organ prolapse at or beyond the hymenal ring Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date Diabetes with peripheral nerve compromise or uncontrolled diabetes Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding Current active or a chronic systemic infection Condition requiring magnetic resonance imaging (MRI) of lower leg Condition requiring diathermy Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane Allergy to local anesthetic or adhesives Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications) Enrolled in another investigational or interventional device or drug trial over the study period",
      "source": "CCT-Adryna",
      "questionnaire": [
        "Are you interested?",
        "Do you actively treat this patient population?",
        "If yes, how many patients do you have in your database with Urinary Incontinence?",
        "How many of those are active and currently under treatment?",
        "On average how many new patients do you get a month?",
        "After I/E review, how many patients do you feel you can enroll in this trial?",
        "Have you done any past trials in this indication?",
        "If yes, how many?",
        "If no, how long have you been treating this patient population?",
        "This study requires a Board-Certified Urologist or Urogynecologist to function as the Principal Investigator and to implant the investigational device, Are you a Board-Certified Urologist?",
        "If no, Are you a board certified Urogynecologist?"
      ]
    },
    {
      "date": "12/25/2021",
      "title": "G",
      "specializations": ["Research Center", "Urology"],
      "applications": [
        {
          "date": "02/25/2022",
          "submitted_by": "Yoany Rodriguez",
          "investigator": "Juvenal Martinez",
          "status": "new",
          "note": "n/a"
        }
      ],
      "description": "We are working with a sponsor on the above mentioned study. If you are interested and treat this indication please let us know. Inclusion Criteria: Women or men 22-80 years of age Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period Greater than or equal to 6-month history of UUI diagnosis Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) Willing to abstain from OAB medications for the duration of the study Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires Ambulatory and able to use the toilet independently and without difficulty Willing and capable of providing informed consent Willing and able to complete all procedures and follow-up visits indicated in the protocol Exclusion Criteria: Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year Have post-void residual urine volume >30% of total voided volume Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS]) History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain) An active implantable electronic device regardless of whether stimulation is ON or OFF Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia) Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula) End stage renal failure, GFR < 35, or dialysis History of pelvic cancer within the past two years Pelvic organ prolapse at or beyond the hymenal ring Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date Diabetes with peripheral nerve compromise or uncontrolled diabetes Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding Current active or a chronic systemic infection Condition requiring magnetic resonance imaging (MRI) of lower leg Condition requiring diathermy Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane Allergy to local anesthetic or adhesives Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications) Enrolled in another investigational or interventional device or drug trial over the study period",
      "source": "CCT-Adryna",
      "questionnaire": [
        "Are you interested?",
        "Do you actively treat this patient population?",
        "If yes, how many patients do you have in your database with Urinary Incontinence?",
        "How many of those are active and currently under treatment?",
        "On average how many new patients do you get a month?",
        "After I/E review, how many patients do you feel you can enroll in this trial?",
        "Have you done any past trials in this indication?",
        "If yes, how many?",
        "If no, how long have you been treating this patient population?",
        "This study requires a Board-Certified Urologist or Urogynecologist to function as the Principal Investigator and to implant the investigational device, Are you a Board-Certified Urologist?",
        "If no, Are you a board certified Urogynecologist?"
      ]
    },
    {
      "date": "02/14/2022",
      "title": "M",
      "specializations": ["Research Center", "Urology"],
      "applications": [
        {
          "date": "02/25/2022",
          "submitted_by": "Yoany Rodriguez",
          "investigator": "Juvenal Martinez",
          "status": "new",
          "note": "n/a"
        }
      ],
      "description": "We are working with a sponsor on the above mentioned study. If you are interested and treat this indication please let us know. Inclusion Criteria: Women or men 22-80 years of age Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period Greater than or equal to 6-month history of UUI diagnosis Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) Willing to abstain from OAB medications for the duration of the study Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires Ambulatory and able to use the toilet independently and without difficulty Willing and capable of providing informed consent Willing and able to complete all procedures and follow-up visits indicated in the protocol Exclusion Criteria: Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year Have post-void residual urine volume >30% of total voided volume Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS]) History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain) An active implantable electronic device regardless of whether stimulation is ON or OFF Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia) Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula) End stage renal failure, GFR < 35, or dialysis History of pelvic cancer within the past two years Pelvic organ prolapse at or beyond the hymenal ring Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date Diabetes with peripheral nerve compromise or uncontrolled diabetes Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding Current active or a chronic systemic infection Condition requiring magnetic resonance imaging (MRI) of lower leg Condition requiring diathermy Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane Allergy to local anesthetic or adhesives Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications) Enrolled in another investigational or interventional device or drug trial over the study period",
      "source": "CCT-Adryna",
      "questionnaire": [
        "Are you interested?",
        "Do you actively treat this patient population?",
        "If yes, how many patients do you have in your database with Urinary Incontinence?",
        "How many of those are active and currently under treatment?",
        "On average how many new patients do you get a month?",
        "After I/E review, how many patients do you feel you can enroll in this trial?",
        "Have you done any past trials in this indication?",
        "If yes, how many?",
        "If no, how long have you been treating this patient population?",
        "This study requires a Board-Certified Urologist or Urogynecologist to function as the Principal Investigator and to implant the investigational device, Are you a Board-Certified Urologist?",
        "If no, Are you a board certified Urogynecologist?"
      ]
    },
    {
      "date": "02/25/2022",
      "title": "Urinary Incontinence CCT02252022",
      "specializations": ["Research Center", "Urology"],
      "applications": [
        {
          "date": "02/25/2022",
          "submitted_by": "Yoany Rodriguez",
          "investigator": "Juvenal Martinez",
          "status": "new",
          "note": "n/a"
        }
      ],
      "description": "We are working with a sponsor on the above mentioned study. If you are interested and treat this indication please let us know. Inclusion Criteria: Women or men 22-80 years of age Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period Greater than or equal to 6-month history of UUI diagnosis Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) Willing to abstain from OAB medications for the duration of the study Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires Ambulatory and able to use the toilet independently and without difficulty Willing and capable of providing informed consent Willing and able to complete all procedures and follow-up visits indicated in the protocol Exclusion Criteria: Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year Have post-void residual urine volume >30% of total voided volume Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS]) History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain) An active implantable electronic device regardless of whether stimulation is ON or OFF Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia) Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula) End stage renal failure, GFR < 35, or dialysis History of pelvic cancer within the past two years Pelvic organ prolapse at or beyond the hymenal ring Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date Diabetes with peripheral nerve compromise or uncontrolled diabetes Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding Current active or a chronic systemic infection Condition requiring magnetic resonance imaging (MRI) of lower leg Condition requiring diathermy Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane Allergy to local anesthetic or adhesives Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications) Enrolled in another investigational or interventional device or drug trial over the study period",
      "source": "CCT-Adryna",
      "questionnaire": [
        "Are you interested?",
        "Do you actively treat this patient population?",
        "If yes, how many patients do you have in your database with Urinary Incontinence?",
        "How many of those are active and currently under treatment?",
        "On average how many new patients do you get a month?",
        "After I/E review, how many patients do you feel you can enroll in this trial?",
        "Have you done any past trials in this indication?",
        "If yes, how many?",
        "If no, how long have you been treating this patient population?",
        "This study requires a Board-Certified Urologist or Urogynecologist to function as the Principal Investigator and to implant the investigational device, Are you a Board-Certified Urologist?",
        "If no, Are you a board certified Urogynecologist?"
      ]
    },
    {
      "date": "02/25/2022",
      "title": "Urinary Incontinence CCT02252022",
      "specializations": ["Research Center", "Urology"],
      "applications": [
        {
          "date": "02/25/2022",
          "submitted_by": "Yoany Rodriguez",
          "investigator": "Juvenal Martinez",
          "status": "new",
          "note": "n/a"
        }
      ],
      "description": "We are working with a sponsor on the above mentioned study. If you are interested and treat this indication please let us know. Inclusion Criteria: Women or men 22-80 years of age Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period Greater than or equal to 6-month history of UUI diagnosis Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) Willing to abstain from OAB medications for the duration of the study Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires Ambulatory and able to use the toilet independently and without difficulty Willing and capable of providing informed consent Willing and able to complete all procedures and follow-up visits indicated in the protocol Exclusion Criteria: Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year Have post-void residual urine volume >30% of total voided volume Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS]) History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain) An active implantable electronic device regardless of whether stimulation is ON or OFF Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia) Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula) End stage renal failure, GFR < 35, or dialysis History of pelvic cancer within the past two years Pelvic organ prolapse at or beyond the hymenal ring Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date Diabetes with peripheral nerve compromise or uncontrolled diabetes Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding Current active or a chronic systemic infection Condition requiring magnetic resonance imaging (MRI) of lower leg Condition requiring diathermy Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane Allergy to local anesthetic or adhesives Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications) Enrolled in another investigational or interventional device or drug trial over the study period",
      "source": "CCT-Adryna",
      "questionnaire": [
        "Are you interested?",
        "Do you actively treat this patient population?",
        "If yes, how many patients do you have in your database with Urinary Incontinence?",
        "How many of those are active and currently under treatment?",
        "On average how many new patients do you get a month?",
        "After I/E review, how many patients do you feel you can enroll in this trial?",
        "Have you done any past trials in this indication?",
        "If yes, how many?",
        "If no, how long have you been treating this patient population?",
        "This study requires a Board-Certified Urologist or Urogynecologist to function as the Principal Investigator and to implant the investigational device, Are you a Board-Certified Urologist?",
        "If no, Are you a board certified Urogynecologist?"
      ]
    },
    {
      "date": "02/25/2022",
      "title": "Urinary Incontinence CCT02252022",
      "specializations": ["Research Center", "Urology"],
      "applications": [
        {
          "date": "02/25/2022",
          "submitted_by": "Yoany Rodriguez",
          "investigator": "Juvenal Martinez",
          "status": "new",
          "note": "n/a"
        }
      ],
      "description": "We are working with a sponsor on the above mentioned study. If you are interested and treat this indication please let us know. Inclusion Criteria: Women or men 22-80 years of age Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period Greater than or equal to 6-month history of UUI diagnosis Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) Willing to abstain from OAB medications for the duration of the study Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires Ambulatory and able to use the toilet independently and without difficulty Willing and capable of providing informed consent Willing and able to complete all procedures and follow-up visits indicated in the protocol Exclusion Criteria: Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year Have post-void residual urine volume >30% of total voided volume Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS]) History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain) An active implantable electronic device regardless of whether stimulation is ON or OFF Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia) Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula) End stage renal failure, GFR < 35, or dialysis History of pelvic cancer within the past two years Pelvic organ prolapse at or beyond the hymenal ring Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date Diabetes with peripheral nerve compromise or uncontrolled diabetes Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding Current active or a chronic systemic infection Condition requiring magnetic resonance imaging (MRI) of lower leg Condition requiring diathermy Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane Allergy to local anesthetic or adhesives Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications) Enrolled in another investigational or interventional device or drug trial over the study period",
      "source": "CCT-Adryna",
      "questionnaire": [
        "Are you interested?",
        "Do you actively treat this patient population?",
        "If yes, how many patients do you have in your database with Urinary Incontinence?",
        "How many of those are active and currently under treatment?",
        "On average how many new patients do you get a month?",
        "After I/E review, how many patients do you feel you can enroll in this trial?",
        "Have you done any past trials in this indication?",
        "If yes, how many?",
        "If no, how long have you been treating this patient population?",
        "This study requires a Board-Certified Urologist or Urogynecologist to function as the Principal Investigator and to implant the investigational device, Are you a Board-Certified Urologist?",
        "If no, Are you a board certified Urogynecologist?"
      ]
    },
    {
      "date": "02/25/2022",
      "title": "Urinary Incontinence CCT02252022",
      "specializations": ["Research Center", "Urology"],
      "applications": [
        {
          "date": "02/25/2022",
          "submitted_by": "Yoany Rodriguez",
          "investigator": "Juvenal Martinez",
          "status": "new",
          "note": "n/a"
        }
      ],
      "description": "We are working with a sponsor on the above mentioned study. If you are interested and treat this indication please let us know. Inclusion Criteria: Women or men 22-80 years of age Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period Greater than or equal to 6-month history of UUI diagnosis Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) Willing to abstain from OAB medications for the duration of the study Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires Ambulatory and able to use the toilet independently and without difficulty Willing and capable of providing informed consent Willing and able to complete all procedures and follow-up visits indicated in the protocol Exclusion Criteria: Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year Have post-void residual urine volume >30% of total voided volume Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS]) History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain) An active implantable electronic device regardless of whether stimulation is ON or OFF Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia) Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula) End stage renal failure, GFR < 35, or dialysis History of pelvic cancer within the past two years Pelvic organ prolapse at or beyond the hymenal ring Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date Diabetes with peripheral nerve compromise or uncontrolled diabetes Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding Current active or a chronic systemic infection Condition requiring magnetic resonance imaging (MRI) of lower leg Condition requiring diathermy Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane Allergy to local anesthetic or adhesives Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications) Enrolled in another investigational or interventional device or drug trial over the study period",
      "source": "CCT-Adryna",
      "questionnaire": [
        "Are you interested?",
        "Do you actively treat this patient population?",
        "If yes, how many patients do you have in your database with Urinary Incontinence?",
        "How many of those are active and currently under treatment?",
        "On average how many new patients do you get a month?",
        "After I/E review, how many patients do you feel you can enroll in this trial?",
        "Have you done any past trials in this indication?",
        "If yes, how many?",
        "If no, how long have you been treating this patient population?",
        "This study requires a Board-Certified Urologist or Urogynecologist to function as the Principal Investigator and to implant the investigational device, Are you a Board-Certified Urologist?",
        "If no, Are you a board certified Urogynecologist?"
      ]
    },
    {
      "date": "02/25/2022",
      "title": "Urinary Incontinence CCT02252022",
      "specializations": ["Research Center", "Urology"],
      "applications": [
        {
          "date": "02/25/2022",
          "submitted_by": "Yoany Rodriguez",
          "investigator": "Juvenal Martinez",
          "status": "new",
          "note": "n/a"
        }
      ],
      "description": "We are working with a sponsor on the above mentioned study. If you are interested and treat this indication please let us know. Inclusion Criteria: Women or men 22-80 years of age Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period Greater than or equal to 6-month history of UUI diagnosis Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) Willing to abstain from OAB medications for the duration of the study Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires Ambulatory and able to use the toilet independently and without difficulty Willing and capable of providing informed consent Willing and able to complete all procedures and follow-up visits indicated in the protocol Exclusion Criteria: Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year Have post-void residual urine volume >30% of total voided volume Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS]) History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain) An active implantable electronic device regardless of whether stimulation is ON or OFF Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia) Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula) End stage renal failure, GFR < 35, or dialysis History of pelvic cancer within the past two years Pelvic organ prolapse at or beyond the hymenal ring Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date Diabetes with peripheral nerve compromise or uncontrolled diabetes Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding Current active or a chronic systemic infection Condition requiring magnetic resonance imaging (MRI) of lower leg Condition requiring diathermy Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane Allergy to local anesthetic or adhesives Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications) Enrolled in another investigational or interventional device or drug trial over the study period",
      "source": "CCT-Adryna",
      "questionnaire": [
        "Are you interested?",
        "Do you actively treat this patient population?",
        "If yes, how many patients do you have in your database with Urinary Incontinence?",
        "How many of those are active and currently under treatment?",
        "On average how many new patients do you get a month?",
        "After I/E review, how many patients do you feel you can enroll in this trial?",
        "Have you done any past trials in this indication?",
        "If yes, how many?",
        "If no, how long have you been treating this patient population?",
        "This study requires a Board-Certified Urologist or Urogynecologist to function as the Principal Investigator and to implant the investigational device, Are you a Board-Certified Urologist?",
        "If no, Are you a board certified Urogynecologist?"
      ]
    },
    {
      "date": "02/25/2022",
      "title": "Urinary Incontinence CCT02252022",
      "specializations": ["Research Center", "Urology"],
      "applications": [
        {
          "date": "02/25/2022",
          "submitted_by": "Yoany Rodriguez",
          "investigator": "Juvenal Martinez",
          "status": "new",
          "note": "n/a"
        }
      ],
      "description": "We are working with a sponsor on the above mentioned study. If you are interested and treat this indication please let us know. Inclusion Criteria: Women or men 22-80 years of age Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period Greater than or equal to 6-month history of UUI diagnosis Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) Willing to abstain from OAB medications for the duration of the study Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires Ambulatory and able to use the toilet independently and without difficulty Willing and capable of providing informed consent Willing and able to complete all procedures and follow-up visits indicated in the protocol Exclusion Criteria: Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year Have post-void residual urine volume >30% of total voided volume Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS]) History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain) An active implantable electronic device regardless of whether stimulation is ON or OFF Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia) Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula) End stage renal failure, GFR < 35, or dialysis History of pelvic cancer within the past two years Pelvic organ prolapse at or beyond the hymenal ring Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date Diabetes with peripheral nerve compromise or uncontrolled diabetes Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding Current active or a chronic systemic infection Condition requiring magnetic resonance imaging (MRI) of lower leg Condition requiring diathermy Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane Allergy to local anesthetic or adhesives Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications) Enrolled in another investigational or interventional device or drug trial over the study period",
      "source": "CCT-Adryna",
      "questionnaire": [
        "Are you interested?",
        "Do you actively treat this patient population?",
        "If yes, how many patients do you have in your database with Urinary Incontinence?",
        "How many of those are active and currently under treatment?",
        "On average how many new patients do you get a month?",
        "After I/E review, how many patients do you feel you can enroll in this trial?",
        "Have you done any past trials in this indication?",
        "If yes, how many?",
        "If no, how long have you been treating this patient population?",
        "This study requires a Board-Certified Urologist or Urogynecologist to function as the Principal Investigator and to implant the investigational device, Are you a Board-Certified Urologist?",
        "If no, Are you a board certified Urogynecologist?"
      ]
    }
  ]
}
